|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||
| Current assets: | ||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||
| Short-term investments (note 5) | ||||||||||||||||
| Short-term marketable securities | ||||||||||||||||
| Accounts receivable | ||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||
| Total current assets | ||||||||||||||||
| Deferred financing fees | ||||||||||||||||
| Long-term investments (note 5) | ||||||||||||||||
| Long-term prepaid assets | ||||||||||||||||
| Long-term marketable securities | ||||||||||||||||
| Long-term prepaids and other assets | ||||||||||||||||
| Deferred tax asset | ||||||||||||||||
| Property and equipment, net | ||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||
| Intangible assets, net | ||||||||||||||||
| Acquired in-process research and development (note 6) | ||||||||||||||||
| Acquired in-process research and development assets (“IPR&D”) (note 6) | ||||||||||||||||
| Goodwill | ||||||||||||||||
| Total assets | ||||||||||||||||
| Liabilities and stockholders’ equity | ||||||||||||||||
| Current liabilities: | ||||||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||||||
| Income tax payable | ||||||||||||||||
| Fair value of liability-classified stock options | ||||||||||||||||
| Current portion of operating lease liability | ||||||||||||||||
| Deferred revenue | ||||||||||||||||
| Total current liabilities | ||||||||||||||||
| Long-term portion of operating lease liability | ||||||||||||||||
| Deferred revenue | ||||||||||||||||
| Liability related to sale of future royalties | ||||||||||||||||
| Other long-term liabilities | ||||||||||||||||
| Deferred tax liability | ||||||||||||||||
| Total liabilities | ||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||
| Common stock, $0.00001 par value; 900,000,000 authorized shares at June 30, 2026 and December 31, 2025, respectively; 71,412,072 and 74,638,413 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||
| Preferred shares, $0.00001 par value; 100,000,000 authorized shares of preferred stock, out of which, one share of preferred stock is a share of Special Voting Preferred Stock and outstanding as of June 30, 2026 and December 31, 2025 | ||||||||||||||||
| Exchangeable shares, no par value, 550,000 and 553,184 issued and outstanding shares at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||
| Additional paid-in capital | ||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||
| Accumulated deficit | ||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||
Loading...
